International Journal of Laboratory Hematology最新文献_第7页

Clinical Laboratories Need More Information About Commercially Available Reagents to Prepare for the IVDR: A Call From the ICSH 临床实验室需要更多关于市售试剂的信息，以准备IVDR：来自ICSH的呼吁。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-26 DOI: 10.1111/ijlh.14506

Dominique Lasne, Sophie Testa, Steve Kitchen, Chris Gardiner, Piet Meijer, François Mullier

Introduction

According to the new In Vitro Diagnostic Medical Device Regulation (EU) (IVDR) an In Vitro Medical Device (IVD) is considered as a laboratory developed test (LDT) if used outside of intended use. It is therefore essential that the information given by the manufacturer about the intended use is clear, precise, and well documented. For now, the only source of information for laboratories is the instructions for use (IFU). Our primary aim was to analyze the IFU provided by several manufacturers for a large panel of coagulation assays. The secondary objective was to provide a list of minimum information that must be accessible to clinical laboratories.

Methods

We analyzed 195 IFU for the main assays used in European hemostasis clinical laboratories commercialized by 12 manufacturers.

Results

The “intended use” section appears in almost all IFU, but the information given in this section is very heterogeneous. We observed disagreement for each of the assays assessed with some intended uses not supported by guidance or guidelines. Some indications in use by clinical laboratories are not provided by the manufacturers. We only found information on clinical performance for a limited number of assays. For some assays, data are available in the literature but are not reported in the IFU. The matrix and the importance of a pre-test probability are not systematically mentioned.

Conclusions

We urgently request access to the necessary information to know the intended use of a reagent according to the IVDR. We define the minimum information that should be available to laboratories. We call for joint discussions to maintain innovation and ensure the quality, safety, and accessibility of innovative diagnostics.

简介：根据新的体外诊断医疗器械法规（EU）（IVDR），体外医疗器械（IVD）如果在预期用途之外使用，则被视为实验室开发的测试（LDT）。因此，制造商提供的有关预期用途的信息必须清晰、准确并有充分的文件记录。目前，实验室唯一的信息来源是使用说明书（IFU）。我们的主要目的是分析几家制造商提供的IFU，用于大型凝血试验。次要目标是提供临床实验室必须可获得的最低限度信息清单。方法：对欧洲12家商业化止血临床实验室主要检测方法的195个IFU进行分析。结果：“预期用途”部分几乎出现在所有IFU中，但该部分给出的信息非常不一致。我们观察到每种测定法的评估存在分歧，其中一些预期用途没有得到指南或指南的支持。临床实验室使用的一些适应症没有由制造商提供。我们只发现了有限数量检测的临床表现信息。对于一些检测，文献中有数据，但在IFU中没有报告。没有系统地提到矩阵和预测概率的重要性。结论：我们迫切要求获得必要的信息，以了解根据IVDR试剂的预期用途。我们定义了应该提供给实验室的最低限度的信息。我们呼吁进行联合讨论，以保持创新，确保创新诊断的质量、安全性和可及性。

{"title":"Clinical Laboratories Need More Information About Commercially Available Reagents to Prepare for the IVDR: A Call From the ICSH","authors":"Dominique Lasne, Sophie Testa, Steve Kitchen, Chris Gardiner, Piet Meijer, François Mullier","doi":"10.1111/ijlh.14506","DOIUrl":"10.1111/ijlh.14506","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>According to the new In Vitro Diagnostic Medical Device Regulation (EU) (IVDR) an In Vitro Medical Device (IVD) is considered as a laboratory developed test (LDT) if used outside of intended use. It is therefore essential that the information given by the manufacturer about the intended use is clear, precise, and well documented. For now, the only source of information for laboratories is the instructions for use (IFU). Our primary aim was to analyze the IFU provided by several manufacturers for a large panel of coagulation assays. The secondary objective was to provide a list of minimum information that must be accessible to clinical laboratories.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed 195 IFU for the main assays used in European hemostasis clinical laboratories commercialized by 12 manufacturers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The “intended use” section appears in almost all IFU, but the information given in this section is very heterogeneous. We observed disagreement for each of the assays assessed with some intended uses not supported by guidance or guidelines. Some indications in use by clinical laboratories are not provided by the manufacturers. We only found information on clinical performance for a limited number of assays. For some assays, data are available in the literature but are not reported in the IFU. The matrix and the importance of a pre-test probability are not systematically mentioned.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We urgently request access to the necessary information to know the intended use of a reagent according to the IVDR. We define the minimum information that should be available to laboratories. We call for joint discussions to maintain innovation and ensure the quality, safety, and accessibility of innovative diagnostics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"938-988"},"PeriodicalIF":2.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How Trustworthy is Light Transmittance Platelet Aggregometry With Low Platelet Count Samples? Insights From Test Replicates and Retrospective Analysis of Several Decades of Diagnostic Samples 低血小板计数样本的透光血小板聚集法可信度如何？从测试重复和回顾性分析几十年的诊断样本的见解。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-23 DOI: 10.1111/ijlh.14518

Catherine P. M. Hayward, Rabab Al Dawood, Lindsay Wice, Karen A. Moffat

Introduction

Light transmission platelet aggregometry (LTA) is useful to diagnose platelet function disorders (PFD). We evaluated the precision and reproducibility of LTA with low platelet count platelet-rich plasma (LPRP).

Methods

LPRP maximal aggregation (MA) precision for informative agonists and LTA reproducibility were assessed using multiple replicates for adjusted control LPRP (CLPRP) and retrospective analysis of several decades of consecutive patient LPRP (PLPRP) and CLPRP tests with replicates between and/or within tests.

Results

Intra-subject CLPRP had acceptable MA CVs and tracings unless platelets were ≤ 25 × 10⁹/L. Among tests with replicates, PLPRP with ≤ 25 × 10⁹ platelets/L were uncommon (6/247 samples) and 5/6 showed pathognomonic Bernard–Soulier syndrome (BSS) findings. Among evaluated patients (n = 195; diverse diagnoses), 44.6% had abnormal LTA findings on ≥ 1 tests after excluding single, within-test MA outliers in 21/194 PLPRP and 2/27 CLPRP tests. Median, intra-subject, within-test coefficients of variation (CVs) for PLPRP and CLPRP MA responses to informative agonists were acceptable for most agonists, with higher CV for 0.5 mg/mL ristocetin, weak agonists, and impaired responses, and only small differences between MA estimates across agonists. Between-test agreement was good for MA responses, with 80.5% of patients and 98.1% of controls having consistent overall LTA findings, with significantly more patients than controls having consistently abnormal LTA findings (46.3% vs. 0%; p < 0.001).

Conclusions

Diagnostic LTA with LPRP has acceptable precision and reproducibility when evaluated with informative agonists. Nonetheless, caution is warranted when testing samples with ≤ 25 × 10⁹ platelets/L, which often show BSS findings.

简介：光透射血小板聚集测定（LTA）是诊断血小板功能障碍（PFD）的有效方法。我们评估了低血小板计数富血小板血浆（LPRP） LTA的精度和再现性。方法：通过调整对照LPRP （CLPRP）的多个重复，以及对数十年连续患者LPRP （PLPRP）和CLPRP试验的回顾性分析（试验之间和/或试验内重复），评估LPRP信息激动剂的最大聚集（MA）精度和LTA重现性。结果：除非血小板≤25 × 109/L，否则受试者内CLPRP具有可接受的MA cv和示图。在重复试验中，血小板≤25 × 109 /L的PLPRP少见（6/247份），5/6份呈病理型Bernard-Soulier综合征（BSS）。在评估的患者中(n = 195；在排除21/194次PLPRP和2/27次CLPRP试验中单个、试验内MA异常值后，44.6%的LTA在≥1次试验中出现异常。PLPRP和CLPRP对信息激动剂的MA反应的中位、受试者内、试验内变异系数（CV）对于大多数激动剂来说是可以接受的，0.5 mg/mL的利司汀、弱激动剂和受损反应的CV更高，并且不同激动剂之间的MA估计只有很小的差异。MA反应的检验间一致性良好，80.5%的患者和98.1%的对照组具有一致的总体LTA结果，明显多于对照组具有一致的异常LTA结果(46.3%对0%；结论：LPRP诊断LTA与信息性激动剂评估时具有可接受的准确性和可重复性。尽管如此，当检测≤25 × 109血小板/L的样本时，需要谨慎，这通常显示BSS的结果。

{"title":"How Trustworthy is Light Transmittance Platelet Aggregometry With Low Platelet Count Samples? Insights From Test Replicates and Retrospective Analysis of Several Decades of Diagnostic Samples","authors":"Catherine P. M. Hayward, Rabab Al Dawood, Lindsay Wice, Karen A. Moffat","doi":"10.1111/ijlh.14518","DOIUrl":"10.1111/ijlh.14518","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Light transmission platelet aggregometry (LTA) is useful to diagnose platelet function disorders (PFD). We evaluated the precision and reproducibility of LTA with low platelet count platelet-rich plasma (LPRP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>LPRP maximal aggregation (MA) precision for informative agonists and LTA reproducibility were assessed using multiple replicates for adjusted control LPRP (CLPRP) and retrospective analysis of several decades of consecutive patient LPRP (PLPRP) and CLPRP tests with replicates between and/or within tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Intra-subject CLPRP had acceptable MA CVs and tracings unless platelets were ≤ 25 × 10<sup>9</sup>/L. Among tests with replicates, PLPRP with ≤ 25 × 10<sup>9</sup> platelets/L were uncommon (6/247 samples) and 5/6 showed pathognomonic Bernard–Soulier syndrome (BSS) findings. Among evaluated patients (<i>n</i> = 195; diverse diagnoses), 44.6% had abnormal LTA findings on ≥ 1 tests after excluding single, within-test MA outliers in 21/194 PLPRP and 2/27 CLPRP tests. Median, intra-subject, within-test coefficients of variation (CVs) for PLPRP and CLPRP MA responses to informative agonists were acceptable for most agonists, with higher CV for 0.5 mg/mL ristocetin, weak agonists, and impaired responses, and only small differences between MA estimates across agonists. Between-test agreement was good for MA responses, with 80.5% of patients and 98.1% of controls having consistent overall LTA findings, with significantly more patients than controls having consistently abnormal LTA findings (46.3% vs. 0%; <i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Diagnostic LTA with LPRP has acceptable precision and reproducibility when evaluated with informative agonists. Nonetheless, caution is warranted when testing samples with ≤ 25 × 10<sup>9</sup> platelets/L, which often show BSS findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 6","pages":"1147-1157"},"PeriodicalIF":2.3,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14518","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accurate Predictor for Successful Collection of Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Lymphoma 多发性骨髓瘤和淋巴瘤患者外周血干细胞成功收集的准确预测因子。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-23 DOI: 10.1111/ijlh.14517

Hongyan Li, Can Yan

引用次数: 0

Flow Cytometric Assessment of TRBC1 Expression for the Diagnosis of T-Cell Lymphoma: Clinical Utility and Pitfalls Related to T-Cell Clones of Uncertain Significance 流式细胞术评估TRBC1表达对t细胞淋巴瘤的诊断：临床应用和与t细胞克隆不确定意义相关的陷阱。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-16 DOI: 10.1111/ijlh.14508

SooHo Yu, Boram Kim, Sang Eun Yoon, Hee-Jin Kim, Hyun-Young Kim

Background

T-cell receptor constant beta chain 1 (TRBC1) has emerged as a potential clonal marker for T-cell lymphoma. This study evaluated TRBC1 expression using flow cytometry in healthy individuals and various clinical specimens, assessing its clinical utility in the diagnosis of T-cell lymphomas.

Methods

Flow cytometric analysis was performed on peripheral blood specimens from 20 healthy individuals and 186 clinical specimens (116 bone marrow aspirates, 18 peripheral bloods, 52 body fluids) from 177 patients for the exclusion or differential diagnosis of T-cell lymphoma using a panel of nine monoclonal antibodies: CD45, CD3, CD4, CD8, CD56, CD2, CD5, CD7, and TRBC1.

Results

TRBC1 showed polytypic expression in healthy individuals with a median of 38.6% (range, 33.9%–46.1%) in CD4+ T cells and 26.3% (range, 10.9%–44.2%) in CD8+ T cells (p < 0.001). TRBC1 expression in non-T-cell lymphoma specimens was comparable to that in healthy peripheral blood, except for bone marrow, which showed slightly higher TRBC1 expression. All 20 T-cell lymphoma cases exhibited monotypic TRBC1 expression, with a predominance of TRBC1− (65%). Additionally, T-cell clones of uncertain significance (TCUS) were detected in 12.7% of non-T-cell lymphoma specimens, predominantly in CD8+ T cells and associated with cytopenic and reactive conditions.

Conclusions

This study demonstrates the clinical utility of flow cytometric TRBC1 assessment in diagnosing T-cell lymphomas, characterizing TRBC1 expression patterns, and identifying TCUS in a large cohort of specimens without T-cell lymphoma involvement across diverse clinical settings. Given the relatively frequent detection of TCUS, these findings underscore the importance of interpreting TRBC1 flow cytometry results within the appropriate clinical context.

背景：t细胞受体恒定β链1 （TRBC1）已成为t细胞淋巴瘤的潜在克隆标记物。本研究利用流式细胞术在健康个体和各种临床标本中评估TRBC1的表达，评估其在诊断t细胞淋巴瘤中的临床应用。方法：采用CD45、CD3、CD4、CD8、CD56、CD2、CD5、CD7、TRBC1等9种单克隆抗体，对20例健康人外周血标本和177例患者186例临床标本（116例骨髓抽取标本、18例外周血标本、52例体液标本）进行流式细胞术分析，排除或鉴别t细胞淋巴瘤。结果：TRBC1在健康个体中呈多型表达，在CD4+ T细胞中中位数为38.6%（范围33.9%-46.1%），在CD8+ T细胞中中位数为26.3%（范围10.9%-44.2%）。(p)结论：本研究证明了流式细胞术TRBC1评估在诊断T细胞淋巴瘤、表征TRBC1表达模式以及在不同临床背景下无T细胞淋巴瘤的大量标本中识别TCUS方面的临床应用。鉴于TCUS的检测相对频繁，这些发现强调了在适当的临床背景下解释TRBC1流式细胞术结果的重要性。

{"title":"Flow Cytometric Assessment of TRBC1 Expression for the Diagnosis of T-Cell Lymphoma: Clinical Utility and Pitfalls Related to T-Cell Clones of Uncertain Significance","authors":"SooHo Yu, Boram Kim, Sang Eun Yoon, Hee-Jin Kim, Hyun-Young Kim","doi":"10.1111/ijlh.14508","DOIUrl":"10.1111/ijlh.14508","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>T-cell receptor constant beta chain 1 (TRBC1) has emerged as a potential clonal marker for T-cell lymphoma. This study evaluated TRBC1 expression using flow cytometry in healthy individuals and various clinical specimens, assessing its clinical utility in the diagnosis of T-cell lymphomas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Flow cytometric analysis was performed on peripheral blood specimens from 20 healthy individuals and 186 clinical specimens (116 bone marrow aspirates, 18 peripheral bloods, 52 body fluids) from 177 patients for the exclusion or differential diagnosis of T-cell lymphoma using a panel of nine monoclonal antibodies: CD45, CD3, CD4, CD8, CD56, CD2, CD5, CD7, and TRBC1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TRBC1 showed polytypic expression in healthy individuals with a median of 38.6% (range, 33.9%–46.1%) in CD4+ T cells and 26.3% (range, 10.9%–44.2%) in CD8+ T cells (<i>p <</i> 0.001). TRBC1 expression in non-T-cell lymphoma specimens was comparable to that in healthy peripheral blood, except for bone marrow, which showed slightly higher TRBC1 expression. All 20 T-cell lymphoma cases exhibited monotypic TRBC1 expression, with a predominance of TRBC1− (65%). Additionally, T-cell clones of uncertain significance (TCUS) were detected in 12.7% of non-T-cell lymphoma specimens, predominantly in CD8+ T cells and associated with cytopenic and reactive conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study demonstrates the clinical utility of flow cytometric TRBC1 assessment in diagnosing T-cell lymphomas, characterizing TRBC1 expression patterns, and identifying TCUS in a large cohort of specimens without T-cell lymphoma involvement across diverse clinical settings. Given the relatively frequent detection of TCUS, these findings underscore the importance of interpreting TRBC1 flow cytometry results within the appropriate clinical context.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"840-848"},"PeriodicalIF":2.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Artificial Lung and Roller Pump on Platelet Morphology and Activation During Simulated Extracorporeal Circulation 人工肺和滚轴泵对模拟体外循环中血小板形态和活化的影响。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-12 DOI: 10.1111/ijlh.14514

Hohomi Arao, Yukinori Kozuma, Tatsuya Furugaki, Tatsuya Kawaguchi, Kazumi Matsushima-Nagata, Ippei Noboruo, Hiroshi Kojima, Yuji Hiramatsu, Yasuyuki Suzuki

Introduction

Prolonged extracorporeal circulation time is known to cause intraoperative and postoperative bleeding, but the underlying mechanism is not fully understood. In this study, we analyzed the effects of artificial lung and roller pump on platelet morphology and activation using a simulated extracorporeal circulatory circuit.

Methods

Blood was drawn from healthy volunteers in the presence of unfractionated heparin as an anticoagulant and recirculated for 180 min at 0.75 L/min with the circuit under a room temperature. After the samples were collected, platelet counts, platelet surface markers, and platelet activation markers were measured.

Results

When whole blood was circulated for 180 min, platelet counts, platelet sizes, and expressions of glycoprotein Ibα (CD42b) and glycoprotein IIb (CD41) significantly decreased after recirculation. In addition, dense bodies and α-granules within platelets were also reduced after recirculation. Adhesion to collagen and platelet aggregation were significantly reduced after recirculation compared to pro-circulation. When platelets were stimulated with A23187 pro- and post-extracorporeal circulation, the expression of P-selectin was significantly lower in CD42b⁻ platelets than in CD42b⁺ platelets. On the other hand, phosphatidylserine (PS) exposure in CD42b⁻ platelets was higher than in CD42b⁺ platelets with or without stimulation.

Conclusion

It was suggested that artificial lungs and roller pumps may reduce platelet activity by causing cleavage of platelet membrane glycoproteins and release of granules within platelets.

导论：体外循环时间延长可引起术中及术后出血，但其潜在机制尚不完全清楚。在本研究中，我们通过模拟体外循环回路分析了人工肺和滚轴泵对血小板形态和活化的影响。方法：健康志愿者在未分离肝素作为抗凝剂的条件下采血，在室温下以0.75 L/min的速度循环180 min。采集标本后，测定血小板计数、血小板表面标志物、血小板活化标志物。结果：全血循环180min后，血小板计数、血小板大小、糖蛋白Ibα (CD42b)、糖蛋白IIb （CD41）表达均明显降低。此外，再循环后血小板内致密体和α-颗粒也减少。与前循环相比，再循环后胶原黏附和血小板聚集明显减少。当A23187体外循环前后刺激血小板时，p -选择素在CD42b-血小板中的表达明显低于CD42b+血小板。另一方面，无论刺激与否，CD42b-血小板中的磷脂酰丝氨酸（PS）暴露高于CD42b+血小板。结论：人工肺和滚轴泵可能通过引起血小板膜糖蛋白的分裂和血小板内颗粒的释放而降低血小板活性。

{"title":"Effects of Artificial Lung and Roller Pump on Platelet Morphology and Activation During Simulated Extracorporeal Circulation","authors":"Hohomi Arao, Yukinori Kozuma, Tatsuya Furugaki, Tatsuya Kawaguchi, Kazumi Matsushima-Nagata, Ippei Noboruo, Hiroshi Kojima, Yuji Hiramatsu, Yasuyuki Suzuki","doi":"10.1111/ijlh.14514","DOIUrl":"10.1111/ijlh.14514","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Prolonged extracorporeal circulation time is known to cause intraoperative and postoperative bleeding, but the underlying mechanism is not fully understood. In this study, we analyzed the effects of artificial lung and roller pump on platelet morphology and activation using a simulated extracorporeal circulatory circuit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Blood was drawn from healthy volunteers in the presence of unfractionated heparin as an anticoagulant and recirculated for 180 min at 0.75 L/min with the circuit under a room temperature. After the samples were collected, platelet counts, platelet surface markers, and platelet activation markers were measured.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>When whole blood was circulated for 180 min, platelet counts, platelet sizes, and expressions of glycoprotein Ibα (CD42b) and glycoprotein IIb (CD41) significantly decreased after recirculation. In addition, dense bodies and α-granules within platelets were also reduced after recirculation. Adhesion to collagen and platelet aggregation were significantly reduced after recirculation compared to pro-circulation. When platelets were stimulated with A23187 pro- and post-extracorporeal circulation, the expression of P-selectin was significantly lower in CD42b<sup>−</sup> platelets than in CD42b<sup>+</sup> platelets. On the other hand, phosphatidylserine (PS) exposure in CD42b<sup>−</sup> platelets was higher than in CD42b<sup>+</sup> platelets with or without stimulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>It was suggested that artificial lungs and roller pumps may reduce platelet activity by causing cleavage of platelet membrane glycoproteins and release of granules within platelets.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 6","pages":"1128-1136"},"PeriodicalIF":2.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RBPJ/PAF1 Signaling Axis Promotes Cloning Expansion in Paroxysmal Nocturnal Hemoglobinuria Through NOTCH Signaling RBPJ/PAF1信号轴通过NOTCH信号传导促进阵发性夜间血红蛋白尿的克隆扩展

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-12 DOI: 10.1111/ijlh.14512

Liyan Li, Junshu Wu, Zewei Chen, Hui Liu, Zhaoyun Liu, Yingying Chen, Honglei Wang, Rong Fu

Background

The pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) is closely related to additional somatic mutations besides PIG-A. Our previous research showed that some PNH patients had a high frequency mutation of RBPJ through whole genome exon sequencing, which played an important role in the pathogenesis of PNH, but its molecular mechanism is still unclear.

Methods

SiRNA transfection was employed to generate RBPJ-knockdown K562 and PNH cell lines. Cell proliferation and apoptosis were assessed via EDU and flow cytometry, respectively. LC–MS following silver staining identified RBPJ-interacting proteins, which were subsequently validated using CO-IP and gradient expression analysis. Western blot examined the relationship between RBPJ, PAF1, and the NOTCH signaling pathway in low-RBPJ-expressing PNH cell lines. The correlation between PAF1 expression, clonal PNH, and RBPJ expression was also analyzed.

Results

Knocking Out RBPJ Leads to Reduced Cell Proliferation and Increased Apoptosis in PNH Cells. We Identified PAF1 as an Interacting Protein of RBPJ and Confirmed the Interaction Domain to Be the BTD Domain of RBPJ. Knocking Out RBPJ Resulted in a Decrease of PAF1 Protein in KO Cell Lines, While the NOTCH1 and HEY1 Protein Expression Related to the NOTCH Signaling Decreased. GSEA Demonstrated That the KO Cell Lines Exhibited a Decreased NOTCH Signaling Pathway Upon PAF1 Downregulation. Knocking Down PAF1 Results in Reduced Protein Levels of NOTCH1 and NOTCH2. Subsequently, After Knocking Out RBPJ With PAF1 Overexpression, NOTCH1 Expression Was Restored, Cell Apoptosis Rate Decreased, and Cell Proliferation Increased. Subsequently, we Observed Elevated PAF1 Expression in PNH Patients, Which Positively Correlated With the FLAER-CD14, FLAER-CD24 and RBPJ mRNA Expression in PNH Patients.

Conclusion

RBPJ/PAF1 may promote PNH clone proliferation by regulating the NOTCH signaling pathway.

背景：阵发性夜间血红蛋白尿（PNH）的发病机制与除猪- a外的其他体细胞突变密切相关。我们前期研究通过全基因组外显子测序发现部分PNH患者存在RBPJ高频突变，该突变在PNH发病中发挥重要作用，但其分子机制尚不清楚。方法：采用SiRNA转染制备rbpj基因敲低的K562和PNH细胞系。分别用EDU和流式细胞术检测细胞增殖和凋亡。银染色后的LC-MS鉴定出rbpj相互作用蛋白，随后使用CO-IP和梯度表达分析对其进行验证。Western blot检测低表达RBPJ的PNH细胞系中RBPJ、PAF1和NOTCH信号通路之间的关系。分析PAF1表达与克隆PNH、RBPJ表达的相关性。结果：敲除RBPJ可使PNH细胞增殖减少，凋亡增加。我们发现PAF1是RBPJ的一个相互作用蛋白，并确定其相互作用结构域为RBPJ的BTD结构域。敲除RBPJ导致KO细胞株中PAF1蛋白表达减少，而与NOTCH信号相关的NOTCH1和HEY1蛋白表达减少。GSEA表明，KO细胞系在PAF1下调后表现出NOTCH信号通路的减少。敲除PAF1导致NOTCH1和NOTCH2蛋白水平降低。随后，PAF1过表达敲除RBPJ后，NOTCH1表达恢复，细胞凋亡率降低，细胞增殖增加。随后，我们观察到PAF1在PNH患者中的表达升高，并与PNH患者中FLAER-CD14、FLAER-CD24和RBPJ mRNA的表达呈正相关。结论：RBPJ/PAF1可能通过调控NOTCH信号通路促进PNH克隆增殖。

{"title":"RBPJ/PAF1 Signaling Axis Promotes Cloning Expansion in Paroxysmal Nocturnal Hemoglobinuria Through NOTCH Signaling","authors":"Liyan Li, Junshu Wu, Zewei Chen, Hui Liu, Zhaoyun Liu, Yingying Chen, Honglei Wang, Rong Fu","doi":"10.1111/ijlh.14512","DOIUrl":"10.1111/ijlh.14512","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) is closely related to additional somatic mutations besides PIG-A. Our previous research showed that some PNH patients had a high frequency mutation of RBPJ through whole genome exon sequencing, which played an important role in the pathogenesis of PNH, but its molecular mechanism is still unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>SiRNA transfection was employed to generate RBPJ-knockdown K562 and PNH cell lines. Cell proliferation and apoptosis were assessed via EDU and flow cytometry, respectively. LC–MS following silver staining identified RBPJ-interacting proteins, which were subsequently validated using CO-IP and gradient expression analysis. Western blot examined the relationship between RBPJ, PAF1, and the NOTCH signaling pathway in low-RBPJ-expressing PNH cell lines. The correlation between PAF1 expression, clonal PNH, and RBPJ expression was also analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Knocking Out RBPJ Leads to Reduced Cell Proliferation and Increased Apoptosis in PNH Cells. We Identified PAF1 as an Interacting Protein of RBPJ and Confirmed the Interaction Domain to Be the BTD Domain of RBPJ. Knocking Out RBPJ Resulted in a Decrease of PAF1 Protein in KO Cell Lines, While the NOTCH1 and HEY1 Protein Expression Related to the NOTCH Signaling Decreased. GSEA Demonstrated That the KO Cell Lines Exhibited a Decreased NOTCH Signaling Pathway Upon PAF1 Downregulation. Knocking Down PAF1 Results in Reduced Protein Levels of NOTCH1 and NOTCH2. Subsequently, After Knocking Out RBPJ With PAF1 Overexpression, NOTCH1 Expression Was Restored, Cell Apoptosis Rate Decreased, and Cell Proliferation Increased. Subsequently, we Observed Elevated PAF1 Expression in PNH Patients, Which Positively Correlated With the FLAER-CD14, FLAER-CD24 and RBPJ mRNA Expression in PNH Patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>RBPJ/PAF1 may promote PNH clone proliferation by regulating the NOTCH signaling pathway.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 6","pages":"1107-1118"},"PeriodicalIF":2.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of WHO-HAEM5 Revisions on the Morphological Interpretation of CLL WHO-HAEM5修订对CLL形态学解释的影响。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-10 DOI: 10.1111/ijlh.14510

Fiamma Balboni, Antonio La Gioia, Fabiana Fiorini, Francesca Di Nezza, Miriam Marsano, Cecilia Vitali, Diego La Gioia, Benedetta Romboli

引用次数: 0

A Single-Center Retrospective Study of the Investigation of Monoclonal B-Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL) in Southwestern Ontario: Are We Over-Investigating? 安大略省西南部单克隆b细胞淋巴细胞增多症（MBL）和慢性淋巴细胞白血病（CLL）的单中心回顾性研究：我们是否过度调查？

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-08 DOI: 10.1111/ijlh.14507

Ortenc Hoxha, Mrinal Lad, Benjamin D. Hedley, Ian H. Chin-Yee, Cyrus C. Hsia, Benjamin Chin-Yee

Introduction

Monoclonal B-cell lymphocytosis (MBL) is a common cause of lymphocytosis in older individuals. Although cytogenetic/molecular testing is usually reserved for patients requiring treatment, recent studies suggest that early testing may have a prognostic benefit in MBL and early-stage chronic lymphocytic leukemia (CLL). We evaluated local practices of expanded diagnostics in the MBL/CLL population to assess (1) adherence to international workshop on CLL (iwCLL) guidelines with respect to additional cytogenetic testing and (2) anticipated costs of expanded diagnostic testing.

Methods

A retrospective chart review was conducted on all patients who underwent flow cytometry testing at our center for a suspected hematologic disorder between 2016 and 2021. Patients were subdivided into CLL, high-count MBL, and low-count MBL, and cytogenetic/molecular testing numbers were calculated as well as associated costs.

Results

Of 974 patients who underwent flow cytometry testing, 100 had CLL, 49 had high-count MBL, and 5 had low-count MBL. Cytogenetic testing was performed in 54/100 CLL, 2/49 high-count MBL, and 0/5 low-count MBL patients. Most testing occurred in symptomatic CLL patients (38/54) especially after the 2018 iwCLL guideline changes. The estimated cost of cytogenetic testing for the 56 patients tested was $27 600. Expanding testing to all patients would have incurred an additional $87 900 during the study period.

Conclusion

This retrospective study shows high adherence to iwCLL guidelines for the investigation of early-stage CLL/MBL, especially after the 2018 guideline changes. Future studies are needed to weigh the benefits of improved prognostication against resources/costs required by expanded cytogenetics/molecular testing in these common hematologic conditions.

单克隆b细胞淋巴细胞增多症（MBL）是老年人淋巴细胞增多症的常见病因。虽然细胞遗传学/分子检测通常是为需要治疗的患者保留的，但最近的研究表明，早期检测可能对MBL和早期慢性淋巴细胞白血病（CLL）的预后有好处。我们评估了MBL/CLL人群中扩展诊断的当地实践，以评估(1)关于额外细胞遗传学检测的CLL国际研讨会（iwCLL）指南的遵守情况；(2)扩展诊断检测的预期成本。方法：对2016年至2021年间在我中心接受疑似血液病流式细胞术检测的所有患者进行回顾性图表回顾。患者被细分为CLL、高计数MBL和低计数MBL，并计算细胞遗传学/分子检测次数以及相关费用。结果：在接受流式细胞术检测的974例患者中，100例为CLL， 49例为高计数MBL， 5例为低计数MBL。细胞遗传学检测在54/100 CLL， 2/49高计数MBL和0/5低计数MBL患者中进行。大多数检测发生在有症状的CLL患者中（38/54），特别是在2018年iwCLL指南变更之后。接受检测的56名患者的细胞遗传学检测费用估计为27 600美元。在研究期间，将测试扩展到所有患者将额外花费87,900美元。结论：本回顾性研究显示，在早期CLL/MBL的研究中，iwCLL指南的依从性很高，特别是在2018年指南变更之后。未来的研究需要权衡改善预后的好处和在这些常见血液病中扩大细胞遗传学/分子检测所需的资源/成本。

{"title":"A Single-Center Retrospective Study of the Investigation of Monoclonal B-Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL) in Southwestern Ontario: Are We Over-Investigating?","authors":"Ortenc Hoxha, Mrinal Lad, Benjamin D. Hedley, Ian H. Chin-Yee, Cyrus C. Hsia, Benjamin Chin-Yee","doi":"10.1111/ijlh.14507","DOIUrl":"10.1111/ijlh.14507","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Monoclonal B-cell lymphocytosis (MBL) is a common cause of lymphocytosis in older individuals. Although cytogenetic/molecular testing is usually reserved for patients requiring treatment, recent studies suggest that early testing may have a prognostic benefit in MBL and early-stage chronic lymphocytic leukemia (CLL). We evaluated local practices of expanded diagnostics in the MBL/CLL population to assess (1) adherence to international workshop on CLL (iwCLL) guidelines with respect to additional cytogenetic testing and (2) anticipated costs of expanded diagnostic testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective chart review was conducted on all patients who underwent flow cytometry testing at our center for a suspected hematologic disorder between 2016 and 2021. Patients were subdivided into CLL, high-count MBL, and low-count MBL, and cytogenetic/molecular testing numbers were calculated as well as associated costs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 974 patients who underwent flow cytometry testing, 100 had CLL, 49 had high-count MBL, and 5 had low-count MBL. Cytogenetic testing was performed in 54/100 CLL, 2/49 high-count MBL, and 0/5 low-count MBL patients. Most testing occurred in symptomatic CLL patients (38/54) especially after the 2018 iwCLL guideline changes. The estimated cost of cytogenetic testing for the 56 patients tested was $27 600. Expanding testing to all patients would have incurred an additional $87 900 during the study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This retrospective study shows high adherence to iwCLL guidelines for the investigation of early-stage CLL/MBL, especially after the 2018 guideline changes. Future studies are needed to weigh the benefits of improved prognostication against resources/costs required by expanded cytogenetics/molecular testing in these common hematologic conditions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"891-897"},"PeriodicalIF":2.3,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14507","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Massive Cryptococcosis in Peripheral Blood Smear 外周血涂片发现大量隐球菌病。

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-06-02 DOI: 10.1111/ijlh.14511

Alba Puyuelo, Cristina Fernández-Maqueda, Laura Benitez-Gutierrez, Isabel Sánchez-Romero, Rafael Forés

引用次数: 0

Correction to “Improving Platelet Function Following Prophylactic Platelet Transfusion in Patients With Hematological Malignancies” 对“血液恶性肿瘤患者预防性输血小板后血小板功能改善”的修正。

IF 2.2 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology

Pub Date : 2025-05-29 DOI: 10.1111/ijlh.14481

Y. F. Wu, C. L. Shen, W. H. Huang, et al., “Improving Platelet Function Following Prophylactic Platelet Transfusion in Patients With Hematological Malignancies,” International Journal of Laboratory Hematology 46, no. 4 (2024): 722–730, https://doi.org/10.1111/ijlh.14283.

In the published article, on page 1 of the “Funding Information,” the text “Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCRD108-73” was incorrect. This should be corrected to: “Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCRD108-73, and Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCMMP112-01-03.”

On page 8 of the “ACKNOWLEDGEMENTS,” the text “This study was supported by a grant (TCRD108-73) from the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.” was incorrect. This should be corrected to: “This study was supported by grants TCRD108-73 from the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, and TCMMP112-01-03 from the Buddhist Tzu Chi Medical Foundation, Hualien Tzu Chi Hospital, Hualien, Taiwan.”

The authors apologize for the error.

吴艳峰，沈春林，黄文慧，等，“血小板输注对恶性血液病患者血小板功能的影响”，中华血液学杂志，第46期，no。4 (2024): 722-730, https://doi.org/10.1111/ijlh.14283.In在“资助信息”第一页的文章中，“花莲慈济医院，佛教慈济医疗基金会，资助/奖励号：TCRD108-73”的文字不正确。应更正为：“花莲慈济医院，佛教慈济医疗基金会，资助/奖励编号：TCRD108-73，佛教慈济医疗基金会，资助/奖励编号：TCMMP112-01-03。”在“致谢”第8页，文字“本研究获得台湾花莲慈济医院、佛教慈济医疗基金会TCRD108-73基金支持”。是不正确的。应更正为：“本研究由台湾花莲慈济医院慈济基金会TCRD108-73和台湾花莲慈济医院慈济基金会TCMMP112-01-03资助。”作者为这个错误道歉。

{"title":"Correction to “Improving Platelet Function Following Prophylactic Platelet Transfusion in Patients With Hematological Malignancies”","authors":"","doi":"10.1111/ijlh.14481","DOIUrl":"10.1111/ijlh.14481","url":null,"abstract":"<p>Y. F. Wu, C. L. Shen, W. H. Huang, et al., “Improving Platelet Function Following Prophylactic Platelet Transfusion in Patients With Hematological Malignancies,” <i>International Journal of Laboratory Hematology</i> 46, no. 4 (2024): 722–730, https://doi.org/10.1111/ijlh.14283.</p><p>In the published article, on page 1 of the “Funding Information,” the text “Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCRD108-73” was incorrect. This should be corrected to: “Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCRD108-73, and Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCMMP112-01-03.”</p><p>On page 8 of the “ACKNOWLEDGEMENTS,” the text “This study was supported by a grant (TCRD108-73) from the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.” was incorrect. This should be corrected to: “This study was supported by grants TCRD108-73 from the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, and TCMMP112-01-03 from the Buddhist Tzu Chi Medical Foundation, Hualien Tzu Chi Hospital, Hualien, Taiwan.”</p><p>The authors apologize for the error.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 4","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14481","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0